Manufacture of Clinical T-cell Products for Future Treatment | Clinical Trial | StuddyBuddy@endsection Manufacture of Clinical T-cell Products for Future Treatment
Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05713513

Manufacture of Clinical T-cell Products for Future Treatment

Conditions: Virus-specific T Cells

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: 1
Enrollment: 9
Sponsor: University Hospital, Basel, Switzerland

Location: Switzerland

Summary

The aim of this pilot study is to validate the manufacture of T-cell products using GMP-approved reagents for future clinical use. Lymphocytes from whole blood of max 300ml from volunteers or from total 9 volunteer apheresates will be isolated to validate the protocol under Good Manufacturing Practice (GMP).

Eligibility Criteria

Inclusion Criteria:signed informed consentImmunoglobulins (Ig) G available for Epstein-Barr virus (EBV) or cytomegalovirus (CMV)Detectable T-cell response for EBV or CMV measured by flow cytometry (> 0.01%)Exclusion Criteria:Infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) or human T-cell lymphoma virus (HTLV)-I/II

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05713513). StuddyBuddy aggregates publicly available trial information.